By Melissa Wildstein | President & Founder, The Matchstick Group | 15+ years in medical device marketing
Last Updated: February 2026
A go-to-market strategy for a Class II medical device is a comprehensive commercialization plan that aligns your regulatory pathway, clinical evidence, value proposition, distribution model, and marketing execution to achieve commercial traction in a regulated market. Class II medical devices represent more than half of all medical devices regulated by the FDA, and most reach market through the 510(k) clearance pathway—a reality that shapes every aspect of your commercialization approach.
Yet having a cleared device is not the same as having a commercial strategy. The 510(k) process tells the FDA your medical device is substantially equivalent to a predicate. It tells the market nothing about why your device is better, who should buy it, or how to get it into the hands of the clinicians who need it. That translation—from regulatory clearance to market adoption—is where a go-to-market medical device strategy lives, and where most medtech companies underinvest.
This guide walks through the seven components of a Class II go-to-market medical device strategy, in the order they should be developed. If you’re looking for the broader launch marketing framework, start with our Complete Guide to Medical Device Product Launch Marketing. If you’re focused on what to complete before you go to market, see our Pre-Launch Marketing Checklist.
Why Does a Class II Medical Device Need a Unique Go-to-Market Strategy?
Not all medical device launches are created equal. A Class II medical device cleared through the 510(k) pathway occupies a specific commercial position that creates both advantages and constraints for your go-to-market strategy.
The 510(k) advantage
First, the 510(k) pathway is faster and less expensive than PMA. Most submissions are reviewed in 90–120 days, and clinical data requirements are typically limited to bench and performance testing rather than full clinical trials. This gives Class II device companies the ability to reach market faster—but it also means your window to build commercial readiness is compressed. The regulatory timeline won’t wait for your marketing team to catch up.
The substantial equivalence constraint
Here’s the rub: the very thing that makes the 510(k) pathway so attractive is also its commercial downside. Because you’re basing your submission on a predicate device, you’re ostensibly telling the FDA that your device is the same. But to the market, you need to paint a completely different and differentiated picture. Your regulatory submission and your commercial positioning are telling two very different stories, and your go-to-market strategy needs to reconcile them.
The competitive density factor
Because the 510(k) pathway is predicate-based, most Class II medical device categories already have multiple players. You’re not creating a new category—you’re entering an established one. That means your go-to-market strategy can’t rely on novelty alone. It has to answer a harder question: why should a hospital, a surgeon, or a purchasing committee switch from what they’re already using?
Step 1: Ground Your Strategy in Customer Insight
Every credible go-to-market strategy starts the same way: with a rigorous understanding of the customer, their environment, and their decision-making process. For Class II devices, this means going far beyond the clinical user.
- Map the full decision-making unit (DMU). In a hospital or health system, a Class II device purchase typically involves 5–7 stakeholders: the clinician who will use the device, the department head, the value analysis committee (VAC), materials management, procurement, a budget holder (often a VP or C-suite executive), and sometimes an adjacent specialist whose domain the device touches (e.g., the head of infection prevention for a surgical device). Each has different evaluation criteria. Your go-to-market strategy needs to address all of them—not just the one who’s most clinically enthusiastic.
- Understand what’s not being said. The most valuable customer insights come from the unstated—the workflow friction that’s been normalized, the purchasing bottleneck that nobody mentions because “that’s just how it works here.” Pay particular attention to clinical workflow. If your device can’t fit within an existing clinical workflow—or requires significant changes to how a team currently operates—it is far more likely to fail commercially, regardless of its clinical merit. A device that adds steps, disrupts sequencing, or requires staff retraining faces an adoption barrier that no amount of marketing can overcome. Understanding the workflow your device must fit into is not optional research—it’s the foundation of your entire value proposition. When we conducted customer research for Avery Dennison’s CDMO rebrand, we discovered that procurement was a gatekeeper that the company hadn’t been addressing at all. That insight didn’t surface in product feedback—it emerged from asking broader questions about how purchasing decisions actually get made.
- Segment by clinical setting and buyer type. A Class II medical device sold into a 500-bed academic medical center follows a completely different buying process than the same device sold into a private practice or ambulatory surgery center (ASC). The clinical value proposition may be identical; the commercial approach is not. Your go-to-market strategy should define distinct playbooks for each segment.
Step 2: Define a Value Proposition That Goes Beyond Clinical Performance
For a Class II medical device, clinical performance is table stakes—it’s the minimum requirement for consideration, not a differentiator. The devices you’re competing against already work. Your value proposition needs to answer a more nuanced question: what value do you deliver beyond the clinical outcome?
The value proposition framework for Class II devices
- Clinical value: Improved outcomes, reduced complications, faster procedures, better accuracy. This is your foundation—but for a 510(k) device, your clinical data may be limited to bench testing and predicate comparison. Be honest about what your evidence supports and what requires post-market data to substantiate.
- Economic value: Reduced procedure time, lower complication rates (and their associated costs), fewer disposables, longer device lifespan, reduced readmissions. In value-based care environments, economic impact is often the deciding factor for administrators and VAC committees. Soft costs are much harder to quantify and realize than hard costs. Do what you can to make those tangible so that the institutions don’t have to guess or extrapolate (hint: cost analysis models work great here).
- Workflow value: Easier setup, faster learning curve, better integration with existing systems, reduced staff training requirements. These advantages frequently determine adoption speed once a purchase decision has been made but the c-suite won’t be sold on this the department heads and floor staff will.
- Strategic value: Does your device enable a new service line? Help the facility meet quality metrics? Support a transition to outpatient settings? Strategic value resonates with C-suite decision-makers who think in terms of organizational capability, not individual device features.
- Revenue-generation value: This is the argument that makes CFOs and CEOs lean forward. Especially for capital equipment, being able to demonstrate ROI is important—but demonstrating that the device is a revenue enabler is transformative. If your platform allows a facility to offer a new billable procedure, attract referrals from a new patient population, increase case volume, or capture market share from a competing institution, you’ve moved beyond cost justification into growth strategy. That’s an entirely different conversation—one that gets budget approval faster and at higher levels of the organization. Frame your device not as an expense to be justified but as an investment that generates return, and you’ll find that the C-suite becomes your champion rather than your obstacle.
🔥 The Positioning Paradox: 510(k) Equivalence vs. Commercial Differentiation
Your 510(k) submission argues substantial equivalence. Your sales team needs to argue meaningful differentiation. The bridge between these two narratives is your value proposition framework. Lead with the clinical and workflow improvements that exist within your cleared indications, then layer in economic and strategic value that doesn’t rely on clinical superiority claims. This is where precise messaging architecture—what you can say, what you can imply, and what requires additional evidence—becomes critical.
Step 3: Build Competitive Positioning That Acknowledges the Landscape
In a predicate-based category, your prospects already have a solution. Your competitive positioning needs to give them a reason to change—and a way to justify that change to every stakeholder involved in the decision.
- Audit every competitor’s positioning, not just their product. What claims are they making? What evidence do they cite? Where are they investing in clinical studies? What does their trade show presence communicate? What are their reps saying in the field? Competitive intelligence should be ongoing, not a one-time exercise during the planning phase.
- Find the white space. The strongest positions in established categories come from occupying territory that competitors have ignored. Maybe they’re all leading with clinical claims and nobody is speaking to the economic buyer. Maybe they’re all targeting large hospital systems and nobody is building a playbook for ASCs. Maybe they’re all focused on surgeons and nobody is addressing the purchasing committee’s evaluation criteria.
- Build a competitive comparison that your sales team can actually use. This isn’t a feature-by-feature matrix—it’s a narrative-driven tool that helps reps articulate why your device is the right choice for each stakeholder.
Step 4: Choose the Right Distribution and Sales Model
How you sell a Class II medical device is as consequential as what you sell. The distribution model you choose will shape your economics, your speed to market, your customer relationships, and your ability to scale.
Distribution model options for Class II medical devices
| Model | Best For | Advantages | Trade-Offs |
|---|---|---|---|
| Direct sales force | High-ASP devices, complex sales, clinical training required | Full control over messaging, deeper customer relationships, clinical expertise | High fixed cost, slower geographic coverage, significant hiring timeline |
| Distributor network | Commodity devices, broad market access, lower ASP products | Rapid geographic coverage, existing relationships, lower fixed cost | Less control over positioning, shared attention with competing products |
| Hybrid model | Mid-range ASP, phased geographic rollout | Direct reps in key markets with distributors for broader coverage | Management complexity, potential channel conflict |
| 1099 independent reps | Early-stage companies, market validation phase | Low fixed cost, built-in networks, quick deployment | Less control, competing priorities, may rely on stale relationships |
| GPO/IDN contracts | Volume-driven devices, large health systems | Institutional access, multi-facility adoption, volume pricing leverage | Long sales cycle, pricing pressure, contract compliance burden |
The right model depends on your device’s average selling price (ASP), the complexity of the clinical sale, the breadth of your target market, and your company’s stage and resources. Many startups begin with 1099 reps or a small direct team in key markets, then layer in distributors as they validate their sales process and scale.
Step 5: Build the Marketing Engine That Drives Awareness and Pipeline
Marketing for a Class II medical device serves two masters: it builds awareness in a market that doesn’t yet know your product exists, and it generates the qualified leads that feed your sales team’s pipeline. Both need to be operating before launch.
Pre-clearance marketing (what you can do now)
- Disease-state and clinical-problem awareness content. You can’t promote an uncleared device, but you can educate the market about the clinical problem it solves. Blog posts, white papers, and educational webinars focused on the condition, the limitations of current approaches, and the unmet need position your company as a thought leader in the space—and build an audience that’s primed for your commercial launch.
- Brand development and identity. Name, visual identity, messaging architecture, and brand guidelines should all be completed before clearance. When we developed the brand for Empyrean Medical Systems, the identity system was ready to deploy across all channels the moment the commercial strategy activated—no scrambling required.
- Digital infrastructure. Website, SEO foundation, marketing automation, analytics—all of this needs to be in place before your first paid campaign runs. The medtech companies that capture early demand are the ones whose digital presence is ready to convert interest into leads from day one.
Post-clearance marketing activation
- Sales enablement and conference strategy. Your sales team needs materials that map to each audience in the DMU, and your first major conference presence needs to be a fully orchestrated launch moment. When we helped introduce EsoGuard to the market, the trade show strategy included pre-show outreach, on-site demonstrations, targeted meetings, and post-show follow-up—all coordinated to maximize a finite window of attention.
- Clinical evidence marketing. For Class II medical devices, clinical evidence often builds over time. Your marketing strategy should include a plan for how you’ll leverage each new data point: initial bench data at launch, early case series at 6–12 months, registry data or comparative studies as they become available. Each data milestone is a marketing moment.
- Demand generation programs. Paid media (LinkedIn, Google, programmatic), email nurture sequences, webinars, and retargeting campaigns should be planned and built pre-clearance, then activated at launch. The most effective demand generation in medtech often combines digital targeting with a tangible value offer. When we built a lead generation program for Synergy Surgical, a specialty suture sample kit promoted to private practice clinics generated over 1,800 qualified leads in six months—proving that the right offer, to the right audience, through the right channel, creates pipeline at scale.
Step 6: Address Market Access and Reimbursement Early
For many Class II medical devices, reimbursement is the commercial gatekeeper. A device that clinicians love but that isn’t adequately reimbursed will struggle to gain institutional adoption, no matter how strong your marketing is.
- Identify your coding pathway. Does an existing CPT or HCPCS code cover procedures performed with your device? If so, what’s the reimbursement level relative to alternatives? If not, what’s the timeline and evidence requirement for pursuing a new code? Marketing and market access strategy need to be aligned, because reimbursement status directly affects which customer segments you can realistically target.
- Build the health economic story. Value analysis committees and hospital CFOs don’t buy devices—they invest in outcomes. Your marketing materials need to translate device features into financial terms: cost per procedure, impact on length of stay, reduction in complications and associated costs, potential for outpatient migration. If you don’t have published health economic data, build a model based on your clinical data and validate it with early adopters.
- Anticipate the payer conversation. Even for devices that don’t require separate reimbursement (because they’re bundled into a facility payment), understanding payer dynamics helps you position your device with hospital administrators who are evaluating total cost of care.
Step 7: Define Your Success Metrics Before You Launch
Just like hope is not a strategy, a go-to-market campaign without measurable milestones is a wish list. Before launch, define the leading and lagging indicators that will tell you whether your strategy is working—and where it needs adjustment.
First 90 days (leading indicators)
- Pipeline creation: How many qualified opportunities has your sales team generated? Not contacts—genuine opportunities with an identified champion, a defined evaluation process, and a timeline.
- Clinical evaluations initiated: How many facilities have agreed to trial or evaluate your device? Evaluation commitments are the strongest early signal of commercial traction.
- Brand awareness baseline: Website traffic, search impression share, trade show engagement, social media following. These are directional, not definitive—but they tell you whether the market is hearing you.
- Digital engagement: Website conversion rate, content download volume, email engagement rates. Are the people visiting your site taking the actions you want them to take?
6–12 months (lagging indicators)
- Revenue and unit adoption vs. plan: Are you hitting the revenue targets defined in your business case?
- Customer acquisition cost (CAC): What does it cost to win each new account? How does that compare to your ASP and lifetime value?
- Sales cycle length: How long from first contact to purchase order? Understanding your sales cycle by customer segment is essential for accurate forecasting.
- Reorder and utilization rates: For disposable or consumable Class II medical devices, reorder rates are the ultimate measure of adoption. For capital devices, utilization rates tell you whether the device is being used or sitting in a closet.
🔥 The Metric That Matters Most Early On
In the first 90 days, the single most important metric is the number of clinical evaluations initiated. Revenue will come, but clinical evaluation commitments are the leading indicator that your value proposition is resonating, your sales process is working, and your marketing is generating the right conversations. If evaluations are stalling, something in your go-to-market strategy needs adjustment—typically the value proposition, the competitive positioning, or the sales team’s ability to articulate both.
How Do These Seven Steps Come Together?
A Class II medical device go-to-market strategy is not a linear document that you write once and file away. It’s a living framework that evolves as you learn from the market. The customer insight you gather in Step 1 will be refined by the field feedback you receive in Step 7. The competitive positioning you build in Step 3 will shift as new players enter your category or existing competitors adjust their approach.
What distinguishes companies that commercialize successfully from those that don’t is rarely the quality of their device. It’s the quality of their go-to-market execution—the speed at which they translate clearance into awareness, awareness into evaluation, and evaluation into adoption.
That execution requires two things most medtech companies underestimate: starting earlier than they think necessary, and investing more in commercial strategy than they’re comfortable with. The 510(k) pathway may be faster than PMA, but the commercial complexity of entering a competitive Class II category is no less demanding. The companies that treat go-to-market planning as an afterthought to regulatory planning are the ones that end up with a cleared device and no market traction.
Frequently Asked Questions
What is the typical timeline for commercializing a Class II medical device?
How is a go-to-market strategy for a Class II medical device different from a Class III device?
How much should a startup budget for go-to-market for a Class II device?
Should we use distributors or a direct sales force for a Class II device?
What’s the most common GTM mistake for Class II medical devices?
Building a go-to-market Strategy for Your Class II Medical Device?
At The Matchstick Group, go-to-market strategy is the core of every engagement. We’ve helped more than 50 medical device companies translate 510(k) clearance into commercial traction—building the brand positioning, sales enablement, digital infrastructure, and demand generation programs that turn a cleared device into an adopted one. Whether you’re 18 months from launch or 90 days out, our Launch and Accelerate programs are designed to match your timeline.
Schedule a call to discuss your Class II commercialization strategy.
